Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT02316002 | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 51 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 |
| clinicaltrials |
| NCT03176173 | Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL) | completed | N/A | 45 | Stanford UniversityOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03396445 | Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | completed | Phase 1 | 182 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Nov 5, 2025 | clinicaltrials |
| NCT03909971 | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | completed | Phase 2 | 109 | PfizerINDUSTRY | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | completed | Phase 3 | 298 | NovoCure GmbHINDUSTRY | 15 | Oct 31, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY | 33 | Oct 30, 2025 | clinicaltrials |
| NCT05018208 | Remote Monitoring in Cancer Care: A Platform Study | completed | — | 100 | Mayo ClinicOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05416983 | Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer | completed | — | 37 | Mayo ClinicOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02599454 | Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 20 | Megan Daly, MDOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT03918304 | Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS(KOREA-PLUS) | completed | — | 923 | AstraZenecaINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05082610 | A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Hummingbird BioscienceINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05639751 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | completed | Phase 1 | 135 | Prelude TherapeuticsINDUSTRY | 5 | Oct 16, 2025 | clinicaltrials |
| NCT03573947 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC(TOP1705) | completed | Phase 2 | 46 | Jeffrey ClarkeOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05640765 | BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers | completed | N/A | 55 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05329623 | A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06180460 | CALM: Managing Distress in Malignant Brain Cancer | completed | N/A | 60 | Virginia Commonwealth UniversityOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT04108026 | Immunotherapy in Patient With Poor General Condition(SAVIMMUNE) | completed | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04631029 | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread | completed | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03833934 | Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance(SPACEWALK) | completed | — | 62 | Addario Lung Cancer Medical InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05386888 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | completed | Phase 2 | 65 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06199050 | The Effect of 360° Virtual Reality Movies on Fear and Anxiety(ENGAGE) | completed | N/A | 292 | Maastricht Radiation OncologyOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05775796 | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) | completed | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201077 | ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery | completed | N/A | 100 | Jianxing HeOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT01172314 | Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients | completed | N/A | 41 | Texas A&M UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04885998 | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 23 | AmgenINDUSTRY | 6 | Sep 29, 2025 | clinicaltrials |
| NCT02111681 | Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer | completed | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT04589247 | Improving Cancer On-treatment Symptom Management(IMPROVE) | completed | — | 104 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | completed | Phase 2 | 85 | BioAtla, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT02719847 | EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy | completed | — | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03801902 | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2025 | clinicaltrials |
| NCT01218854 | A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy | completed | Phase 1 | 17 | National Institutes of Health Clinical Center (CC)NIH | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186855 | Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC | completed | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01812031 | Benefits Study of Respiratory-gated PET Acquisition in Lung Disease(PneumoTEP) | completed | N/A | 103 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06261294 | OncoSweep Cancer Spotlight and Spectrum Product Line | completed | — | 109 | Pharus Taiwan, Inc.INDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05014815 | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 272 | BeiGeneINDUSTRY | 8 | Sep 16, 2025 | clinicaltrials |
| NCT02493114 | Physical Functioning Throughout Lung Cancer Treatment(LUCAT) | completed | — | 150 | Hasselt UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04575025 | Special Drug Use-results Surveillance of Tabrecta Tablets | completed | — | 109 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04892342 | Study of ESG401 in Adults With Solid Tumors | completed | Phase 1 / Phase 2 | 156 | Shanghai Escugen Biotechnology Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT03786653 | Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)(ImHADom) | completed | — | 10 | RENAULT Patrick AldoOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05219162 | Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).(GPS) | completed | Phase 4 | 182 | AstraZenecaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04221529 | Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide(SPACE) | completed | Phase 2 | 70 | AIO-Studien-gGmbHOTHER | 2 | Sep 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 10, 2025source: clinicaltrials